|
US6022683A
(en)
*
|
1996-12-16 |
2000-02-08 |
Nova Molecular Inc. |
Methods for assessing the prognosis of a patient with a neurodegenerative disease
|
|
US6441149B1
(en)
|
1998-06-15 |
2002-08-27 |
Mitokor |
Diagnostic method based on quantification of extramitochondrial DNA
|
|
US6218117B1
(en)
|
1998-06-15 |
2001-04-17 |
Mitokor |
Compositions and methods for identifying agents that quantitatively alter detectable extramitochondrial DNA:mitochondrial DNA ratios
|
|
US6489095B2
(en)
|
1998-06-15 |
2002-12-03 |
Mitokor |
Diagnostic method based on quantification of extramitochondrial DNA
|
|
EP1088104B1
(en)
*
|
1998-06-16 |
2006-02-08 |
Nova Molecular, Inc. |
Methods for treating a neurological disease by determining bche genotype
|
|
WO2000020634A1
(en)
|
1998-10-01 |
2000-04-13 |
Nova Molecular, Inc. |
Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant gpiiia and/or variant gpiib allele
|
|
WO2000070340A2
(en)
*
|
1999-05-14 |
2000-11-23 |
Karolinska Innovations Ab |
Materials and methods relating to disease diagnosis
|
|
DE1233365T1
(de)
*
|
1999-06-25 |
2003-03-20 |
Genaissance Pharmaceuticals Inc., New Haven |
Verfahren zur herstellung und verwendung von Haplotype Daten
|
|
US7058517B1
(en)
|
1999-06-25 |
2006-06-06 |
Genaissance Pharmaceuticals, Inc. |
Methods for obtaining and using haplotype data
|
|
US6692916B2
(en)
*
|
1999-06-28 |
2004-02-17 |
Source Precision Medicine, Inc. |
Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
|
|
US6960439B2
(en)
*
|
1999-06-28 |
2005-11-01 |
Source Precision Medicine, Inc. |
Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
|
|
US6573049B1
(en)
|
1999-07-26 |
2003-06-03 |
Nuvelo, Inc. |
Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease
|
|
US6896881B1
(en)
*
|
1999-09-24 |
2005-05-24 |
Mayo Foundation For Medical Education And Research |
Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
|
|
AU2001240820A1
(en)
*
|
2000-03-15 |
2001-09-24 |
Oxford Glycosciences (Uk) Ltd. |
Proteins, genes and their use for diagnosis and treatment of vascular dementia
|
|
US20080009467A1
(en)
*
|
2000-05-01 |
2008-01-10 |
Accera, Inc. |
Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
|
|
US20070179197A1
(en)
*
|
2000-05-01 |
2007-08-02 |
Accera, Inc. |
Compositions and methods for improving or preserving brain function
|
|
US8124589B2
(en)
|
2000-05-01 |
2012-02-28 |
Accera, Inc. |
Use of ketogenic compounds for treatment of age-associated memory impairment
|
|
US6835750B1
(en)
|
2000-05-01 |
2004-12-28 |
Accera, Inc. |
Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
|
|
WO2001082928A1
(en)
*
|
2000-05-01 |
2001-11-08 |
Accera, Inc. |
Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
|
|
US6931326B1
(en)
|
2000-06-26 |
2005-08-16 |
Genaissance Pharmaceuticals, Inc. |
Methods for obtaining and using haplotype data
|
|
US6399310B1
(en)
|
2001-02-12 |
2002-06-04 |
Akzo Nobel N.V. |
Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
|
|
WO2002064735A2
(en)
*
|
2001-02-12 |
2002-08-22 |
Akzo Nobel N.V. |
Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4
|
|
US20030105082A1
(en)
*
|
2001-12-03 |
2003-06-05 |
Murphy Greer Marechal |
Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
|
|
GB0106051D0
(en)
*
|
2001-03-12 |
2001-05-02 |
Isis Innovation |
Diagnostic screens for alzheimer's disease
|
|
US20030104453A1
(en)
*
|
2001-11-06 |
2003-06-05 |
David Pickar |
System for pharmacogenetics of adverse drug events
|
|
EP1451340B1
(en)
|
2001-11-09 |
2014-01-08 |
Life Technologies Corporation |
Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
|
|
US20030224446A1
(en)
*
|
2001-12-20 |
2003-12-04 |
Harry G. Jean |
Method of predicting cytokine response to tissue injury
|
|
US20040267458A1
(en)
*
|
2001-12-21 |
2004-12-30 |
Judson Richard S. |
Methods for obtaining and using haplotype data
|
|
WO2003069431A2
(en)
*
|
2002-02-14 |
2003-08-21 |
Medavante, Inc. |
System and method for facilitating candidate and subject participation in clinical trial studies
|
|
US7432355B2
(en)
*
|
2002-08-09 |
2008-10-07 |
The J. David Gladstone Institutes |
Apolipoprotein E stable folding intermediate and methods of use thereof
|
|
US8688385B2
(en)
|
2003-02-20 |
2014-04-01 |
Mayo Foundation For Medical Education And Research |
Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
|
|
EP1636592B1
(en)
*
|
2003-06-19 |
2012-12-19 |
Merck Serono SA |
Use of prion conversion modulating agents
|
|
US20050038692A1
(en)
*
|
2003-08-14 |
2005-02-17 |
Kane John Michael |
System and method for facilitating centralized candidate selection and monitoring subject participation in clinical trial studies
|
|
EP1706837A2
(en)
*
|
2004-01-16 |
2006-10-04 |
Disease Management Services, Plc |
Disease management system
|
|
KR20070033032A
(ko)
|
2004-07-16 |
2007-03-23 |
프로테오시스 악티엔게젤샤프트 |
세포보호제로서 ｐａｒｐ 및 ｓｉｒ 조절 활성을 갖는무스카린 길항제
|
|
US20060252775A1
(en)
*
|
2005-05-03 |
2006-11-09 |
Henderson Samuel T |
Methods for reducing levels of disease associated proteins
|
|
EP2468273A3
(en)
*
|
2005-06-20 |
2012-07-11 |
Accera, Inc. |
Method to reduce oxidative damage and improve mitochondrial efficiency
|
|
CA2630604C
(en)
*
|
2005-11-29 |
2016-01-19 |
Children's Hospital Medical Center |
Optimization and individualization of medication selection and dosing
|
|
US20080126118A1
(en)
*
|
2006-11-24 |
2008-05-29 |
General Electric Company, A New York Corporation |
Systems, methods and apparatus for a network application framework system
|
|
TWI362012B
(en)
*
|
2007-07-23 |
2012-04-11 |
|
System of providing hygienic education information and method thereof
|
|
ES2556534T3
(es)
|
2007-07-31 |
2016-01-18 |
Accera, Inc. |
Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida
|
|
US20090198504A1
(en)
*
|
2008-02-05 |
2009-08-06 |
Medavante, Inc. |
Rater resource allocation systems and methods
|
|
US9125881B2
(en)
*
|
2008-07-03 |
2015-09-08 |
Accera, Inc. |
Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
|
|
US8105809B2
(en)
*
|
2008-07-03 |
2012-01-31 |
Accera, Inc. |
Enzymatic synthesis of acetoacetate esters and derivatives
|
|
EP2387405A2
(en)
|
2009-01-13 |
2011-11-23 |
ProteoSys AG |
Pirenzepine as an agent in cancer treatment
|
|
EP2360280A1
(en)
*
|
2010-02-24 |
2011-08-24 |
Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol |
Genetic marker for the diagnosis of dementia with Lewy bodies
|
|
US20120078521A1
(en)
*
|
2010-09-27 |
2012-03-29 |
General Electric Company |
Apparatus, system and methods for assessing drug efficacy using holistic analysis and visualization of pharmacological data
|
|
US20130080182A1
(en)
*
|
2011-09-26 |
2013-03-28 |
Athleticode Inc. |
Methods For Using DNA Testing To Screen For Genotypes Relevant To Athleticism, Health And Risk Of Injury
|
|
RU2467680C1
(ru)
*
|
2011-10-04 |
2012-11-27 |
Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации |
Способ прогнозирования эффективности лечения больных ишемическим инсультом
|
|
US10665328B2
(en)
|
2014-06-30 |
2020-05-26 |
QIAGEN Redwood City, Inc. |
Methods and systems for interpretation and reporting of sequence-based genetic tests
|
|
US10658073B2
(en)
|
2014-08-15 |
2020-05-19 |
QIAGEN Redwood City, Inc. |
Methods and systems for interpretation and reporting of sequence-based genetic tests using pooled allele statistics
|
|
EP3628315A1
(en)
|
2018-09-28 |
2020-04-01 |
Université de Caen Normandie |
Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases
|
|
WO2020091375A2
(ko)
*
|
2018-10-29 |
2020-05-07 |
고려대학교 산학협력단 |
항우울제 추천 방법 및 시스템
|